Answers are grounded in this paper and cite their sources.
Objectives This study investigated the therapeutic potential of striosomes in addressing ICSDs, focusing on the treatment response of tic and obsessive-compulsive (OC) symptoms in tic-related OCD (T-OCD) to a pharmacological intervention designed to enhance striosomal dopamine signaling through D1-type receptors (D1Rs). Methods Ten participants with T-OCD [30% male; mean age, 40.5 years (SD 20.1); mean age at onset, 9.2 years (SD 4.1)] received L-DOPA/carbidopa (50 mg) plus chlorpromazine-phenolphthalinate (5 mg), with doses increased stepwise to three times daily over 8 weeks, then maintained for 1 year. We used the Yale Global Tic Severity Scale (YGTSS) and the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) for clinical assessments. For statistical analyses, we used repeated-measures ANOVA with Dunnett’s post hoc tests and calculated partial eta squared (η 2 ) to report effect sizes. Results The study cohort showed significant, sustained improvements in both tics and OCD symptoms. At one-year follow-up, Total Tic Severity Scale scores on the YGTSS decreased by 73.3% ( n = 10; mean difference, −11.0; 95% CI, −13.99 to −8.04; p = 0.0025; η 2 = 0.715) compared with the baseline. In parallel, Y-BOCS scores decreased by 85.1% ( n = 10; mean difference, −13.10; 95% CI, −17.71 to −8.49; p = 0.0004; η 2 = 0.639). No adverse effects were reported during this one-year study. Conclusion Pharmacologic modulation of striosomal D 1 R signaling could provide significant, durable benefits for patients with T-OCD. Given its efficacy and safety in reducing both tic and OC symptoms in T-OCD, striosomes may serve as a promising therapeutic target for ICSDs. These findings warrant further investigation through larger, randomized, and placebo-controlled clinical trials.
No takes yet. Share an insight, caveat, or question.
Matsumoto et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: